SABSライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (29 4月 2024 @ 22:50):

Stats
本日の出来高	1 860.00
平均出来高	13 575.00
時価総額	38.56M
EPS	$0 ( 2024-04-01 )
次の収益日	( $0 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.550
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-21	Kropotova Alexandra	Buy	140 000	Employee Stock Option (right to buy)
2024-02-21	Sullivan Eddie Joe	Buy	190 000	Employee Stock Option (right to buy)
2024-02-21	Bausch Christoph Lawrence	Buy	140 000	Employee Stock Option (right to buy)
2024-02-21	King Michael	Buy	115 000	Employee Stock Option (right to buy)
2024-02-21	Reich Samuel J	Buy	434 000	Employee Stock Option (right to buy)

INSIDER POWER
70.14
Last 88 transactions
Buy: 19 783 333 \| Sell: 3 137 658

SAB Biotherapeutics, Inc. 相関

10 最も正の相関
SHBI	0.924
RXT	0.912
POTX	0.907
MVST	0.905
WSBC	0.902
VNDA	0.9
BCAB	0.9
SPFI	0.899
OPHC	0.898
UCBI	0.897

10 最も負の相関
RMRM	-0.93
APOP	-0.915
IIN	-0.882
EXFO	-0.881
TIG	-0.874
MLVF	-0.873
AUPH	-0.872
EVCM	-0.871
SUMR	-0.871
CARG	-0.869

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

SAB Biotherapeutics, Inc. 財務諸表

Annual	2023
収益:	$2.24M
総利益:	$-1.51M (-67.28 %)
EPS:	$-7.64

FY	2023
収益:	$2.24M
総利益:	$-1.51M (-67.28 %)
EPS:	$-7.64

FY	2022
収益:	$23.90M
総利益:	$20.61M (86.23 %)
EPS:	$-4.31

FY	2021
収益:	$60.88M
総利益:	$0.00 (0.00 %)
EPS:	$-0.394

Financial Reports:

No articles found.

SAB Biotherapeutics, Inc.

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases comprising COVID-19 and influenza, immune and autoimmune disorders, such as type 1 diabetes, organ transplantation, and cancer. The company uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors. Its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development to treat or prevent severe influenza. The company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. The company was founded in 2014 and is based in Sioux Falls, South Dakota.